Shattuck Labs to Host Conference Call and Webcast Highlighting Data Presented at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 04 2021 - 6:00AM
Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage
biotechnology company pioneering the development of bi-functional
fusion proteins as a new class of biologic medicine for the
treatment of patients with cancer and autoimmune disease with three
ongoing Phase 1 clinical trials, today announced it will host
a live webcast presentation highlighting the clinical data being
presented at the 2021 Society for Immunotherapy of Cancer on
Friday, November 12, 2021 at 8:00 a.m. ET.
The event will be led by Taylor Schreiber, M.D., Ph.D., Chief
Executive Officer of Shattuck, and will include presentations by
Lini Pandite, MBChB, M.B.A., Chief Medical Officer of Shattuck and
Andrew Neill, M.B.A., Chief Financial Officer of Shattuck. During
the event, the company will highlight dose-escalation data for
SL-172154 (SIRPα-Fc-CD40L), its lead bi-functional fusion protein
designed to simultaneously inhibit the CD47/SIRPα checkpoint
interaction and activate the CD40 costimulatory receptor, in
platinum-resistant ovarian cancer patients, and dose-escalation
data for SL-279252 (PD1-Fc-OX40L), which is designed to
simultaneously inhibit the PD-1/PD-L1 interaction and activate the
OX40 receptor, in patients with advanced solid tumors or lymphoma.
Members of Shattuck leadership will be available to answer
questions at the end of the event.
The live call may be accessed by dialing (833) 614-1555
(domestic) or (516) 575-8754 (international) and entering the
conference code: 4068596. The live and archived webcast will be
available on the Events & Presentations section of the
Company’s website. A replay of the webcast will be archived for up
to 90 days following the presentation date.
About Shattuck Labs, Inc.Shattuck is a
clinical-stage biotechnology company pioneering the development of
bi-functional fusion proteins as a new class of biologic medicine
for the treatment of patients with cancer and autoimmune disease.
Compounds derived from Shattuck’s proprietary Agonist Redirected
Checkpoint, ARC®, platform simultaneously inhibit checkpoint
molecules and activate costimulatory molecules within a single
therapeutic. The company’s lead wholly owned program, SL-172154
(SIRPα-Fc-CD40L), which is designed to block the CD47 immune
checkpoint and simultaneously agonize the CD40 pathway, is being
evaluated in two Phase 1 trials. A second compound, SL-279252
(PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in
collaboration with Takeda Pharmaceuticals. Additionally, the
company is advancing a proprietary Gamma Delta T Cell Engager,
GADLEN™, platform, which is designed to bridge gamma delta T cells
to tumor antigens for the treatment of patients with cancer.
Shattuck has offices in both Austin, Texas and Durham, North
Carolina. For more information, please visit:
www.ShattuckLabs.com.
Investor Contact: Conor RichardsonSenior
Director, Finance & Investor RelationsShattuck Labs,
Inc.InvestorRelations@shattucklabs.com
Media Contact:Stephanie Ascher Managing
DirectorStern Investor Relations,
Inc.Stephanie.ascher@sternir.com
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jul 2023 to Jul 2024